Stryker Launches Trident II Acetabular System in India for Precision Hip Replacements

IMT News Desk
IMT News Desk
· 2 min read
Stryker launches Trident II Acetabular System in India for advanced hip replacements.

Advanced THA Solution Features Tritanium Technology, Mako Robotics Compatibility to Boost Stability

Stryker, a global leader in medical technologies, launched the Trident II Acetabular System in India to advance total hip arthroplasty (THA) outcomes. This next-generation hip replacement platform delivers superior precision, stability, and surgeon confidence amid rising osteoarthritis cases and aging populations.

The Trident II builds on Stryker’s proven legacy, holding the distinction of the most implanted acetabular shell in the Australian Orthopaedic Association National Joint Replacement Registry for 20 consecutive years. It integrates cutting-edge Tritanium In-Growth Technology or PureFix HA for enhanced osseointegration, supporting diverse patient anatomies and surgical techniques.

Aman Rishi, Vice President & General Manager, India, Stryker, stated, “Hip replacement surgeries are rising globally due to ageing populations and rising incidence of osteoarthritis and mobility-related disorders. With the launch of the Trident II Acetabular System, we reinforce our commitment to bringing clinically proven, innovation-led solutions to surgeons and their patients. By combining advanced materials, data-backed design and robotic-arm assisted capabilities, Trident II represents a significant step forward in hip replacement solutions.”

Key features include compatibility with Mako SmartRobotics™ for precise implantation, the Innerchange Locking Mechanism for intraoperative flexibility with Modular Dual Mobility options to minimize dislocation risks, and X3 highly crosslinked polyethylene liners for superior wear resistance and oxidation stability.

This launch underscores Stryker’s focus on innovation-driven orthopaedics, equipping Indian surgeons with tools to optimize long-term THA success and patient mobility.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk